89 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
MAIA Soars 20% on Interim Results From Lung Cancer Study https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212386 Jan 18, 2024 - MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
Novo Nordisk (NVO) Upgraded to Strong Buy: What Does It Mean for the Stock? https://www.zacks.com/stock/news/2212339/novo-nordisk-nvo-upgraded-to-strong-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2212339 Jan 18, 2024 - Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term https://www.zacks.com/stock/news/2212144/why-novo-nordisk-nvo-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2212144 Jan 18, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Best Growth Stocks to Buy for January 16th https://www.zacks.com/commentary/2210722/best-growth-stocks-to-buy-for-january-16th?cid=CS-ZC-FT-zacks_1_rank_additions|growth_additions-2210722 Jan 16, 2024 - NVO, AIZ and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 16, 2024.
Here is Why Growth Investors Should Buy Novo Nordisk (NVO) Now https://www.zacks.com/stock/news/2210387/here-is-why-growth-investors-should-buy-novo-nordisk-nvo-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-2210387 Jan 15, 2024 - Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Novo Nordisk (NVO) Is Up 2.45% in One Week: What You Should Know https://www.zacks.com/stock/news/2210353/novo-nordisk-nvo-is-up-2-45-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2210353 Jan 15, 2024 - Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152 Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
UnitedHealth Group (UNH) Q4 Earnings Beat on Membership Growth https://www.zacks.com/stock/news/2209723/unitedhealth-group-unh-q4-earnings-beat-on-membership-growth?cid=CS-ZC-FT-analyst_blog|earnings_article-2209723 Jan 12, 2024 - UnitedHealth Group's (UNH) Q4 results benefit on the back of double-digit revenue growth in its UnitedHealthcare and Optum segments. Management maintains its 2024 adjusted EPS target within $27.50-$28.00.
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718 Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026 Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.

Pages: 123456789

<<<Page 5>